title: Dosimetry study of [I-131] and [I-125]- meta-iodobenz guanidine in a simulating model for neuroblastoma metastasis.
abstract: The physical properties of I-131 may be suboptimal for the delivery of therapeutic radiation to bone marrow metastases, which are common in the natural history of neuroblastoma.  In vitro and preliminary clinical studies have implied improved efficacy of I-125 relative to I-131 in certain clinical situations, although areas of uncertainty remain regarding intratumoral dosimetry. This prompted our study using human neuroblastoma multicellular spheroids as a model of metastasis. 3D dose calculations were made using voxel-based Medical Internal Radiation Dosimetry (MIRD) and dose-point-kernel (DPK) techniques. Dose distributions for I-131 and I-125 labeled mIBG were calculated for spheroids (metastases) of various sizes from 0.01 cm to 3 cm diameter, and the relative dose delivered to the tumors was compared for the same limiting dose to the bone marrow. Based on the same data, arguments were advanced based upon the principles of tumor control probability (TCP) to emphasize the potential theoretical utility of I-125 over I-131 in specific clinical situations. I-125-mIBG can deliver a higher and more uniform dose to tumors compared to I-131 mIBG without increasing the dose to the bone marrow. Depending on the tumor size and biological half-life, the relative dose to tumors of less than 1 mm diameter can increase several-fold. TCP calculations indicate that tumor control increases with increasing administered activity, and that I-125 is more effective than I-131 for tumor diameters of 0.01 cm or less. This study suggests that I-125-mIBG is dosimetrically superior to I-131-mIBG therapy for small bone marrow metastases from neuroblastoma. It is logical to consider adding I-125-mIBG to I-131-mIBG in multi-modality therapy as these two isotopes could be complementary in terms of their cumulative dosimetry.
authors.affiliation: Divisions of Radiation Oncology, University of Alberta/Cross Cancer Institute, Edmonton, Alberta, Canada. wilson.roa@albertahealthservices.ca
authors.forename: W H
authors.initials: WH
authors.lastname: Roa
authors.forename: B
authors.initials: B
authors.lastname: Yaremko
authors.forename: A
authors.initials: A
authors.lastname: McEwan
authors.forename: J
authors.initials: J
authors.lastname: Amanie
authors.forename: D
authors.initials: D
authors.lastname: Yee
authors.forename: J
authors.initials: J
authors.lastname: Cho
authors.forename: S
authors.initials: S
authors.lastname: McQuarrie
authors.forename: T
authors.initials: T
authors.lastname: Riauka
authors.forename: R
authors.initials: R
authors.lastname: Sloboda
authors.forename: L
authors.initials: L
authors.lastname: Wiebe
authors.forename: R
authors.initials: R
authors.lastname: Loebenberg
authors.forename: C
authors.initials: C
authors.lastname: Janicki
mesh_terms: D019797:3-Iodobenzylguanidine / Q000378:metabolism*; D000465:Algorithms; D003198:Computer Simulation; D007457:Iodine Radioisotopes / Q000378:metabolism*; D008954:Models, Biological; D009362:Neoplasm Metastasis; D009447:Neuroblastoma / Q000473:pathology* / Q000532:radiotherapy*; D011874:Radiometry
chemical_list: D007457:Iodine Radioisotopes; D019797:3-Iodobenzylguanidine